カテゴリー： MarketsandMarkets, 世界, 医療/バイオ

世界の創薬における人工知能（AI）市場（～2028年）：提供別、工程別（ターゲット選択、バリデーション、リード生成、最適化）、ドラッグデザイン別（低分子、ワクチン、抗体、PK/PD）、ドライラボ別、ウェットラボ別（シングルセル解析）、地域別

◆英語タイトル：Artificial Intelligence / AI in Drug Discovery Market by Offering, Process (Target selection, Validation, Lead generation, optimization), Drug Design (Small molecule, Vaccine, Antibody, PK/PD), Dry Lab, Wet Lab (Single Cell analysis) & Region - Global Forecast to 2028
	◆商品コード：HIT7445-23 ◆発行会社（リサーチ会社）：MarketsandMarkets ◆発行日：2023年11月13日 ◆ページ数：369 ◆レポート形式：英語 / PDF ◆納品方法：Eメール（受注後24時間以内） ◆調査対象地域：グローバル ◆産業分野：製薬

◆販売価格オプション（消費税別）

Single User（1名様閲覧）	USD4,950 ⇒換算￥742,500	見積依頼/購入/質問フォーム
Multi User (Five User)	USD6,650 ⇒換算￥997,500	見積依頼/購入/質問フォーム
Corporate License (全社内共有可)	USD8,150 ⇒換算￥1,222,500	見積依頼/購入/質問フォーム

★MarketsandMarketsに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

“創薬における人工知能（AI）市場は、2023年の9億米ドルから2028年には49億米ドルに達し、予測期間中の年平均成長率は40.2％になると予測”AIは、複雑な生物学的データを分析することで、潜在的な創薬ターゲットの特定と検証を迅速化します。これにより、治療介入に生物学的に関連する標的の選択が加速されます。機械学習などのAI技術は、迅速な分析と意思決定を可能にし、創薬プロセスに必要な時間とリソースを削減します。この効率化により、ペースの速い医薬品業界において競争力を高めることができます。したがって、前述の要因はこの市場の成長を促進するでしょう。一方、熟練労働者の不足は、予測期間中、市場の成長をある程度抑制する主な要因です。

“サービス分野は2022年に主要シェアを占めると推定され、また予測期間中に最も高い成長が見込み”
提供に基づき、創薬AI市場はソフトウェアとサービスに二分されます。2022年の世界の創薬AIサービス市場では、ソフトウェアとサービスが最大の市場シェアを占め、予測期間中の年平均成長率も最も高くなると予測されています。サービスを通じてAI技術や専門知識にアクセスできるため、製薬企業が創薬にAIを導入する際の障壁が低くなります。これは、社内に大規模なAI能力を持たない中小企業にとって特に有益であり、多額の先行投資を行うことなくAIの力を活用することができます。

“機械学習技術分野が世界の創薬AI市場で最大シェアを占める”
技術に基づき、創薬AI市場は機械学習、自然言語処理（NLP）、コンテキスト認識処理、その他の技術に区分されます。機械学習分野は2022年に世界市場で最大のシェアを占め、予測期間中に最も高いCAGRで成長する見込みです。機械学習は、潜在的な医薬品候補の人体内での挙動を予測する予測モデルの作成を可能にします。これにより、成功の可能性が最も高い化合物を特定し、失敗した候補に関連するコストと時間を削減することができます。機械学習は、患者データを分析して薬剤に対する個々の反応を予測することで、個別化治療戦略の開発に貢献します。これにより、遺伝子情報、分子情報、臨床情報に基づいて治療法を調整することが容易になり、より効果的な治療結果が得られ、創薬プロセスの加速につながることが、このセグメントの市場成長を支える要因の一部となっています。

“2022年、低分子設計・最適化分野がユースケース分野で最大シェアを占める見込み”
ユースケースに基づき、創薬AI市場は、低分子設計・最適化、疾患・安全性・毒性の理解、ワクチン設計・最適化、抗体・その他生物製剤設計・最適化に分けられます。2022年には、低分子設計・最適化分野が創薬AI市場で最大のシェアを占めました。AIが低分子化合物の設計と最適化に採用される主な目的は2つあります。第一に、既存の化学ライブラリーをスクリーニングしたり、ジェネレーティブなde novoデザインによって、ヒット化合物やリード化合物を同定するのに役立ちます。第二に、AIは同定されたヒット化合物を最適化し、結合親和性、毒性、合成などの有利な特性を確保します。これらの要素は、創薬のユースケースに合わせたAIアルゴリズムの開発と改良に貢献しています。

“2022年に創薬AI市場を支配するのは北米”
世界の創薬AI市場は、北米、ヨーロッパ、アジア太平洋、その他の地域の4つの主要地域に区分されます。2022年には、北米が創薬AIで最大かつ最も急成長している地域市場を占めています。北米には、創薬におけるAIの能力を積極的に探求している数多くの製薬大手やバイオテクノロジー・イノベーターが存在します。これらの業界大手はAIを活用した研究開発に多額の投資を行っており、市場の成長を牽引しています。北米では医薬品とヘルスケアに関する規制の枠組みが確立されているため、業界標準とガイドラインの遵守を確保しながらAI技術の統合を促進することができます。以上のような要因が、北米における創薬AI市場を牽引すると考えられます。

供給側、需要側、一次インタビューの内訳は以下の通りです（企業タイプ別、呼称別、地域別）：
- 企業タイプ別：
- 供給サイド別：ティア1（31％）、ティア2（28％）、ティア3（41％）
- 需要サイド別：購買マネージャー（45％）、人工知能、機械学習、創薬、計算分子設計の責任者（30％）、研究科学者（25％）。
- 役職別： Cレベル(31％)、ディレクターレベル(25％)、その他(44％)
- 地域別：北米（45％）、ヨーロッパ（20％）、アジア太平洋（28％）、南米（4％）、中東・アフリカ（3％）

同市場における主要企業は、NVIDIA Corporation (US), Exscientia (UK), BenevolentAI (UK), Recursion (US), Insilico Medicine (US), Schrödinger, Inc. (US), Microsoft Corporation (US), Google (US), Atomwise Inc. (US), Illumina, Inc. (US), NuMedii, Inc. (US), XtalPi Inc. (US), Iktos (France), Tempus Labs (US), Deep Genomics, Inc. (Canada), Verge Genomics (US), BenchSci (Canada), Insitro (US), Valo Health (US), BPGbio, Inc. (US), IQVIA Inc (US), Labcorp (US), Tencent Holdings Limited (China), Predictive Oncology, Inc. (US), Celsius Therapeutics (US), CytoReason (Israel), Owkin, Inc. (US), Cloud Pharmaceuticals (US), Evaxion Biotech (Denmark), Standigm (South Korea), BIOAGE (US), Envisagenics (US), and Aria Pharmaceuticals, Inc. (US)などが含まれます。各社は、製品の上市や機能強化、投資、提携、共同事業、資金調達、買収、拡大、契約、販売契約、提携などの有機的および無機的な成長戦略を採用し、提供製品を増やし、顧客の満たされていないニーズに対応し、収益性を高め、世界市場でのプレゼンスを拡大しています。

調査範囲：
- 当レポートでは、創薬AI市場を提供、技術、治療分野、ユースケース、プロセス、エンドユーザー、地域に基づいて調査しています。
- 市場成長に影響を与える要因（促進要因、阻害要因、機会、課題など）を分析しています。
- 関係者向けに市場の機会と課題を評価し、市場リーダー向けに競争環境の詳細を提供します。
- 当レポートでは、創薬AI市場の成長動向、将来性、市場全体への貢献に関してミクロ市場を調査しています。
- 主要5地域に関して市場セグメントの収益を予測しています。

レポート購入の理由：
本レポートは、既存企業だけでなく、新規参入企業や小規模企業が市場の動向を把握するのに役立ち、ひいては、より大きなシェアを獲得するのに役立ちます。本レポートを購入される企業は、以下の5つの戦略を1つまたは組み合わせて使用することができます。

本レポートは、以下のポイントに関する洞察を提供します：
 創薬AI市場の成長に影響を与える主な促進要因（異業種連携やパートナーシップの増加、創薬・開発コストの抑制と医薬品開発期間の短縮に対するニーズの高まり、複数の医薬品の特許切れ）、阻害要因（AI人材の不足、医療用ソフトウェアに関する曖昧な規制ガイドライン）、機会（バイオテクノロジー産業の成長、新興市場、人間を認識するAIシステムの開発に注力、COVID-19パンデミックにもかかわらず医薬品・生物製剤市場の成長）、課題（データセットの限られた利用可能性）の分析を提供しています。
 製品開発／イノベーション：創薬AI市場における今後の技術、研究開発活動、製品発売に関する詳細な洞察を記載しています。
 市場開発：有利な新興市場に関する包括的情報を掲載しています。本レポートでは、地域別に様々なタイプの創薬AIソリューションの市場を分析します。
 市場の多様化：創薬AI市場における製品、未開拓地域、最近の開発、投資に関する情報を網羅。
 競合評価：創薬AI市場における主要企業の市場シェア、戦略、製品、流通網、製造能力を詳細に評価を提供しています。

1.　イントロダクション
2.　調査方法
3.　エグゼクティブサマリー
4.　プレミアムインサイト
5.　市場概要
6.　産業動向
7.　世界の創薬における人工知能（AI）市場規模：提供別
8.　世界の創薬における人工知能（AI）市場規模：技術別
9.　世界の創薬における人工知能（AI）市場規模：治療領域別
10.　世界の創薬における人工知能（AI）市場規模：工程別
11.　世界の創薬における人工知能（AI）市場規模：使用事例別
12.　世界の創薬における人工知能（AI）市場規模：エンドユーザー別
13.　世界の創薬における人工知能（AI）市場規模：地域別
14.　競争環境
15.　企業情報
16.　付録

❖ レポートの目次 ❖

1 INTRODUCTION 38
1.1 STUDY OBJECTIVES 38
1.2 MARKET DEFINITION 38
1.2.1 INCLUSIONS AND EXCLUSIONS 39
1.3 MARKET SCOPE 40
1.3.1 MARKET SEGMENTATION 40
FIGURE 1 AI IN DRUG DISCOVERY MARKET: MARKET SEGMENTATION 40
1.3.2 REGIONAL SCOPE 41
1.3.3 YEARS CONSIDERED 41
1.3.4 CURRENCY CONSIDERED 42
TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 42
1.4 STAKEHOLDERS 42
1.5 SUMMARY OF CHANGES 43
1.5.1 RECESSION IMPACT 44
2 RESEARCH METHODOLOGY 45
2.1 RESEARCH DATA 45
FIGURE 2 RESEARCH DESIGN 45
2.2 SECONDARY SOURCES 46
2.2.1 KEY DATA FROM SECONDARY SOURCES 47
2.3 PRIMARY DATA 47
2.3.1 PRIMARY SOURCES 48
2.3.1.1 Key data from primary sources 49
2.3.1.2 Key industry insights 50
2.3.2 BREAKDOWN OF PRIMARY INTERVIEWS 50
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY DEMAND SIDE,
SUPPLY SIDE, DESIGNATION, AND REGION 50
2.4 MARKET SIZE ESTIMATION 51
FIGURE 4 SUPPLY-SIDE MARKET ESTIMATION: REVENUE SHARE ANALYSIS 52
FIGURE 5 BOTTOM-UP APPROACH: END-USER SPENDING ON AI IN DRUG DISCOVERY 53
TABLE 2 FACTOR ANALYSIS 55
FIGURE 6 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2022–2027) 56
FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 56
FIGURE 8 TOP-DOWN APPROACH 57
2.5 MARKET BREAKDOWN AND DATA TRIANGULATION 58
FIGURE 9 DATA TRIANGULATION METHODOLOGY 58

2.6 ASSUMPTIONS 59
2.6.1 MARKET SIZING ASSUMPTIONS 59
2.6.2 OVERALL STUDY ASSUMPTIONS 59
2.7 LIMITATIONS 60
2.8 RISK ASSESSMENT 60
TABLE 3 RISK ASSESSMENT: AI IN DRUG DISCOVERY MARKET 60
2.9 RECESSION IMPACT ANALYSIS 61
TABLE 4 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH) 61
TABLE 5 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION) 61
TABLE 6 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION) 62
3 EXECUTIVE SUMMARY 63
FIGURE 10 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2023 VS. 2028 (USD MILLION) 63
FIGURE 11 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION) 64
FIGURE 12 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2023 VS. 2028 (USD MILLION) 64
FIGURE 13 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS,
2023 VS. 2028 (USD MILLION) 65
FIGURE 14 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE,
2023 VS. 2028 (USD MILLION) 66
FIGURE 15 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 66
FIGURE 16 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET: GEOGRAPHICAL SNAPSHOT 67
4 PREMIUM INSIGHTS 68
4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN AI IN DRUG DISCOVERY MARKET 68
FIGURE 17 GROWING NUMBER OF CROSS-INDUSTRY COLLABORATIONS & PARTNERSHIPS TO DRIVE MARKET 68
4.2 AI IN DRUG DISCOVERY MARKET: REGIONAL LANDSCAPE 69
FIGURE 18 NORTH AMERICA TO DOMINATE AI IN DRUG DISCOVERY MARKET DURING FORECAST PERIOD 69
4.3 AI IN DRUG DISCOVERY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 69
FIGURE 19 US TO REGISTER HIGHEST REVENUE GROWTH FROM 2023 TO 2028 69
4.4 NORTH AMERICAN AI IN DRUG DISCOVERY MARKET, BY END USER & COUNTRY, 2022 70
FIGURE 20 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND US HELD LARGEST SHARE IN NORTH AMERICA, 2022 70
4.5 AI IN DRUG DISCOVERY MARKET, BY OFFERING 70
FIGURE 21 SERVICES TO HOLD MAJORITY MARKET SHARE IN 2028 70
4.6 AI IN DRUG DISCOVERY MARKET, BY TECHNOLOGY 71
FIGURE 22 MACHINE LEARNING TO RETAIN MARKET LEADERSHIP TILL 2028 71
4.7 AI IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA 71
FIGURE 23 ONCOLOGY TO DOMINATE MARKET IN 2028 71
4.8 AI IN DRUG DISCOVERY MARKET, BY PROCESS 72
FIGURE 24 HIT-TO LEAD IDENTIFICATION/LEAD GENERATION TO DOMINATE MARKET IN 2028 72
4.9 AI IN DRUG DISCOVERY MARKET, BY USE CASE 72
FIGURE 25 SMALL MOLECULE DESIGN & OPTIMIZATION TO REGISTER HIGHEST GROWTH OVER FORECAST PERIOD 72
4.10 AI IN DRUG DISCOVERY MARKET, BY END USER 73
FIGURE 26 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO ACCOUNT FOR LARGEST MARKET SHARE IN 2028 73
5 MARKET OVERVIEW 74
5.1 INTRODUCTION 74
5.2 MARKET DYNAMICS 74
FIGURE 27 AI IN DRUG DISCOVERY: MARKET DYNAMICS 74
TABLE 7 AI IN DRUG DISCOVERY MARKET: IMPACT ANALYSIS 75
5.2.1 DRIVERS 75
5.2.1.1 Growing cross-industry collaborations and partnerships 75
TABLE 8 INDICATIVE LIST OF COLLABORATIONS AND PARTNERSHIPS (2021−2023) 76
5.2.1.2 Growing need to reduce time and cost of drug discovery and development 77
5.2.1.3 Patent expiry of several drugs 77
TABLE 9 INDICATIVE LIST OF DRUGS LOSING PATENTS IN 2023 78
5.2.2 RESTRAINTS 78
5.2.2.1 Shortage of AI workforce and ambiguous regulatory guidelines for medical software 78
5.2.3 OPPORTUNITIES 79
5.2.3.1 Growing biotechnology industry 79
5.2.3.2 Emerging markets 79
5.2.3.3 Focus on developing human-aware AI systems 80
5.2.4 CHALLENGES 80
5.2.4.1 Limited availability of data sets 80
5.2.4.2 Lack of required tools and usability 80
6 INDUSTRY INSIGHTS 82
6.1 OVERVIEW OF KEY INDUSTRY TRENDS 82
6.1.1 EVOLUTION OF AI IN DRUG DISCOVERY 82
FIGURE 28 EVOLUTION OF AI IN DRUG DISCOVERY MARKET 83
6.1.2 COMPUTER-AIDED DRUG DESIGN AND AI 84
FIGURE 29 STRUCTURE-BASED DRUG DESIGNING: AI IN DRUG DISCOVERY MARKET 84
6.2 SUPPLY CHAIN ANALYSIS 84
FIGURE 30 AI IN DRUG DISCOVERY MARKET: SUPPLY CHAIN ANALYSIS (2022) 85
6.3 PORTER’S FIVE FORCES ANALYSIS 85
TABLE 10 AI IN DRUG DISCOVERY MARKET: PORTER’S FIVE FORCES ANALYSIS 85
6.3.1 INTENSITY OF COMPETITIVE RIVALRY 85
6.3.2 BARGAINING POWER OF BUYERS 85
6.3.3 BARGAINING POWER OF SUPPLIERS 86
6.3.4 THREAT OF SUBSTITUTES 86
6.3.5 THREAT OF NEW ENTRANTS 86
6.4 ECOSYSTEM/MARKET MAP 86
FIGURE 31 AI IN DRUG DISCOVERY MARKET ECOSYSTEM 86
6.5 TECHNOLOGY ANALYSIS 87
FIGURE 32 AI IN DRUG DISCOVERY MARKET: CLASSIFICATION 87
6.5.1 DRY LAB SERVICES 87
6.5.2 WET LAB SERVICES 90
6.5.2.1 Chemistry services 90
6.5.2.2 BIOLOGICAL SERVICES 91
6.5.2.2.1 Single-cell analysis 92
6.6 PRICING ANALYSIS 95
6.6.1 AVERAGE SELLING PRICE TRENDS, BY REGION 95
6.6.2 INDICATIVE PRICING ANALYSIS, BY PROCESS 96
TABLE 11 AI IN DRUG DISCOVERY MARKET: INDICATIVE PRICING, BY PROCESS 96
6.7 BUSINESS MODELS 96
FIGURE 33 AI IN LIFE SCIENCES: BUSINESS MODELS 97
FIGURE 34 BENEFITS OF HYBRID BUSINESS MODELS 97
FIGURE 35 SPECIALIZATION OF AI COMPANIES OVER TIME 98
6.8 CASE STUDY ANALYSIS 99
6.8.1 CASE STUDY 1: BRISTOL MYERS SQUIBB AND EXSCIENTIA 99
6.8.2 CASE STUDY 2: APEIRON LLC AND EXSCIENTIA 100
6.9 REGULATORY ANALYSIS 101
6.9.1 AI IN DRUG DISCOVERY MARKET: REGULATORY LANDSCAPE, BY REGION 101
6.9.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 103
TABLE 12 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 103
6.10 PATENT ANALYSIS 104
FIGURE 36 TOP PATENT OWNERS AND APPLICANTS FOR AI IN DRUG DISCOVERY SOLUTIONS (JANUARY 2011–OCTOBER 2023) 104
FIGURE 37 AI IN DRUG DISCOVERY MARKET: PATENT ANALYSIS (JANUARY 2011–OCTOBER 2023) 105
FIGURE 38 TOP APPLICANT COUNTRIES/REGIONS FOR AI IN DRUG DISCOVERY PATENTS (JANUARY 2012–JULY 2023) 105
TABLE 13 LIST OF PATENTS/PATENT APPLICATIONS IN AI IN DRUG DISCOVERY MARKET, 2021–2023 106
6.11 KEY CONFERENCES & EVENTS (Q1 2023–Q2 2024) 108
6.12 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 109
FIGURE 39 REVENUE SHIFT IN AI IN DRUG DISCOVERY MARKET 109
6.13 KEY STAKEHOLDERS & BUYING CRITERIA 109
6.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 109
FIGURE 40 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF AI IN DRUG DISCOVERY MARKET 109
6.13.2 BUYING CRITERIA FOR AI IN DRUG DISCOVERY MARKET 110
FIGURE 41 KEY BUYING CRITERIA FOR END USERS 110
6.14 AI-DERIVED CLINICAL ASSETS 110
TABLE 14 KEY AI-DERIVED CLINICAL ASSETS, BY COMPANY 110
6.15 UNMET NEEDS 120
6.15.1 UNMET NEEDS IN AI IN DRUG DISCOVERY 120
6.15.2 SINGLE-CELL ANALYSIS LANDSCAPE: KEY CHALLENGES AND PAIN POINTS IN DRUG DISCOVERY 121
6.15.3 KEY UNMET NEEDS AND PAIN POINTS FOR AI APPLICATIONS IN SINGLE-CELL ANALYSIS FOR DRUG DISCOVERY 122
7 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING 123
7.1 INTRODUCTION 124
TABLE 15 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021–2028 (USD MILLION) 124
7.2 SERVICES 124
7.2.1 SERVICES SEGMENT TO WITNESS HIGHEST GROWTH 124
TABLE 16 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SERVICES, BY COUNTRY, 2021–2028 (USD MILLION) 125
7.3 SOFTWARE 125
7.3.1 BENEFITS OF SOFTWARE IN DRUG DISCOVERY AND STRONG DEMAND AMONG END USERS TO DRIVE GROWTH 125
TABLE 17 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SOFTWARE, BY COUNTRY, 2021–2028 (USD MILLION) 126
8 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY 127
8.1 INTRODUCTION 128
TABLE 18 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 128
8.2 MACHINE LEARNING 128
TABLE 19 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 129
TABLE 20 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY COUNTRY, 2021–2028 (USD MILLION) 129
8.2.1 DEEP LEARNING 130
8.2.1.1 Deep learning to see growing adoption in drug discovery 130
TABLE 21 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR DEEP LEARNING, BY COUNTRY, 2021–2028 (USD MILLION) 130
8.2.2 SUPERVISED LEARNING 131
8.2.2.1 Applications in drug repositioning to drive market 131
TABLE 22 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR SUPERVISED LEARNING, BY COUNTRY, 2021–2028 (USD MILLION) 131
8.2.3 REINFORCEMENT LEARNING 132
8.2.3.1 Potential for machines and software to automatically determine behavior to support adoption 132
TABLE 23 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR REINFORCEMENT LEARNING, BY COUNTRY, 2021–2028 (USD MILLION) 132
8.2.4 UNSUPERVISED LEARNING 133
8.2.4.1 Unpredictability to affect end-user adoption 133
TABLE 24 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR UNSUPERVISED LEARNING, BY COUNTRY, 2021–2028 (USD MILLION) 133
8.2.5 OTHER MACHINE LEARNING TECHNOLOGIES 134
TABLE 25 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER MACHINE LEARNING TECHNOLOGIES, BY COUNTRY, 2021–2028 (USD MILLION) 134
8.3 NATURAL LANGUAGE PROCESSING 135
8.3.1 POTENTIAL APPLICATIONS IN DATA IDENTIFICATION TO SUPPORT GROWTH 135
TABLE 26 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NATURAL LANGUAGE PROCESSING, BY COUNTRY, 2021–2028 (USD MILLION) 135
8.4 CONTEXT-AWARE PROCESSING & CONTEXT-AWARE COMPUTING 136
8.4.1 RISING PROCESSING POWER, IMPROVED CONNECTIVITY TO BOOST USAGE 136
TABLE 27 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CONTEXT-AWARE PROCESSING & CONTEXT-AWARE COMPUTING, BY COUNTRY, 2021–2028 (USD MILLION) 136
8.5 OTHER TECHNOLOGIES 137
TABLE 28 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2021–2028 (USD MILLION) 138
9 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET,
BY THERAPEUTIC AREA 139
9.1 INTRODUCTION 140
TABLE 29 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 140
9.2 ONCOLOGY 140
9.2.1 HIGH PREVALENCE OF CANCER AND SHORTAGE OF EFFECTIVE CANCER DRUGS TO DRIVE SEGMENT GROWTH 140
TABLE 30 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 141
9.3 INFECTIOUS DISEASES 141
9.3.1 RISING EPIDEMIC OUTBREAKS TO BOOST DRUG DISCOVERY ACTIVITY 141
TABLE 31 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 142
9.4 NEUROLOGY 143
9.4.1 NEED TO BOOST DISCOVERY AND DEVELOPMENT TO DRIVE MARKET 143
TABLE 32 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR NEUROLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 143
9.5 CARDIOVASCULAR DISEASES 144
9.5.1 RISING DEMAND FOR CVD DRUGS TO DRIVE SEGMENT 144
TABLE 33 INDICATIVE LIST OF DEVELOPMENTS IN CARDIOVASCULAR DRUG DEVELOPMENT 144
TABLE 34 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 145
9.6 IMMUNOLOGY 145
9.6.1 GROWING DRUG PIPELINE FOR IMMUNOLOGICAL DISORDERS TO FAVOR MARKET GROWTH 145
TABLE 35 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR IMMUNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 146
9.7 METABOLIC DISEASES 146
9.7.1 ROLE OF AI IN UNCOVERING SMALL-MOLECULE THERAPIES TO DRIVE ADOPTION 146
TABLE 36 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 147
9.8 OTHER THERAPEUTIC AREAS 148
TABLE 37 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2021–2028 (USD MILLION) 148
10 AI IN DRUG DISCOVERY MARKET, BY PROCESS 149
10.1 INTRODUCTION 150
FIGURE 42 HIT-TO-LEAD IDENTIFICATION/LEAD GENERATION SEGMENT HELD LARGEST MARKET SHARE IN 2022 150
TABLE 38 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021–2028 (USD MILLION) 150
10.2 TARGET IDENTIFICATION & SELECTION 151
10.2.1 DEVELOPMENT OF NEW TECHNOLOGIES TO SUPPORT MARKET GROWTH 151
TABLE 39 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR TARGET IDENTIFICATION & SELECTION, BY COUNTRY, 2021–2028 (USD MILLION) 152
10.3 TARGET VALIDATION 152
10.3.1 RISING EMPHASIS ON TARGET VALIDATION TO AVOID LATE-STAGE FAILURE 152
TABLE 40 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR TARGET VALIDATION, BY COUNTRY, 2021–2028 (USD MILLION) 153
10.4 HIT IDENTIFICATION & PRIORITIZATION 154
10.4.1 NEED FOR LARGE-SCALE DATA ANALYSIS TO DRIVE ADOPTION 154
TABLE 41 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR HIT IDENTIFICATION & PRIORITIZATION, BY COUNTRY, 2021–2028 (USD MILLION) 154
10.5 HIT-TO-LEAD IDENTIFICATION/LEAD GENERATION 155
10.5.1 HIT-TO-LEAD IDENTIFICATION TO HOLD LARGEST MARKET SHARE 155
TABLE 42 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR HIT-TO-LEAD IDENTIFICATION/LEAD GENERATION, BY COUNTRY, 2021–2028 (USD MILLION) 156
10.6 LEAD OPTIMIZATION 156
10.6.1 NEED FOR TRANSPARENT PRESENTATION AND ANALYSIS TO BOOST FOCUS ON LEAD OPTIMIZATION 156
TABLE 43 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2021–2028 (USD MILLION) 157
10.7 CANDIDATE SELECTION & VALIDATION 158
10.7.1 POSSIBILITY OF DRUG FAILURE DURING DEVELOPMENT TO DRIVE ADOPTION OF CANDIDATE VALIDATION SERVICES 158
TABLE 44 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CANDIDATE SELECTION & VALIDATION, BY COUNTRY, 2021–2028 (USD MILLION) 159
11 AI IN DRUG DISCOVERY MARKET, BY USE CASE 160
11.1 INTRODUCTION 161
FIGURE 43 SMALL-MOLECULE DESIGN & OPTIMIZATION SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022 161
TABLE 45 AI IN DRUG DISCOVERY MARKET, BY USE CASE, 2021–2028 (USD MILLION) 162
11.2 SMALL-MOLECULE DESIGN & OPTIMIZATION 162
11.2.1 AVAILABILITY OF WELL-VALIDATED AI TOOLS TO BOOST MARKET GROWTH 162
TABLE 46 AI IN DRUG DISCOVERY MARKET FOR SMALL-MOLECULE DESIGN & OPTIMIZATION, BY COUNTRY, 2021–2028 (USD MILLION) 163
11.3 UNDERSTANDING DISEASE 164
11.3.1 RISING DATA MINING TO LINK TARGETS TO DISEASES AND DRUG REPURPOSING TO DRIVE MARKET 164
TABLE 47 AI IN DRUG DISCOVERY MARKET FOR UNDERSTANDING DISEASE, BY COUNTRY, 2021–2028 (USD MILLION) 165
11.4 SAFETY & TOXICITY 165
11.4.1 TOXICOLOGY AND OFF-TARGET EFFECT PREDICTION, PK/PD SIMULATION, AND QSP MODELING TO PROPEL MARKET GROWTH 165
TABLE 48 AI IN DRUG DISCOVERY MARKET FOR SAFETY & TOXICITY, BY COUNTRY, 2021–2028 (USD MILLION) 167
11.5 VACCINE DESIGN & OPTIMIZATION 167
11.5.1 GROWING ADOPTION OF AI FOR EPITOPE SELECTION, PREDICTION, AND BINDING TO AUGMENT MARKET GROWTH 167
TABLE 49 AI IN DRUG DISCOVERY MARKET FOR VACCINE DESIGN & OPTIMIZATION, BY COUNTRY, 2021–2028 (USD MILLION) 168
11.6 ANTIBODY & OTHER BIOLOGIC DESIGN & OPTIMIZATION 169
11.6.1 GROWING ADOPTION OF AI FOR ANTIBODY PROPERTY PREDICTION TO DRIVE MARKET 169
TABLE 50 AI IN DRUG DISCOVERY MARKET FOR ANTIBODY & OTHER BIOLOGIC DESIGN & OPTIMIZATION, BY COUNTRY, 2021–2028 (USD MILLION) 170
12 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER 171
12.1 INTRODUCTION 172
TABLE 51 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021–2028 (USD MILLION) 172
12.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 172
12.2.1 RISING DEMAND FOR SOLUTIONS TO CUT TIME AND COSTS OF DRUG DEVELOPMENT TO DRIVE MARKET 172
TABLE 52 INDICATIVE LIST OF DEVELOPMENTS RELATED TO AI IN PHARMACEUTICAL & BIOTECHNOLOGY INDUSTRY 173
TABLE 53 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 174
12.3 CONTRACT RESEARCH ORGANIZATIONS 175
12.3.1 GROWING TREND OF OUTSOURCING TO PROVIDE SIGNIFICANT OPPORTUNITIES FOR CONTRACT RESEARCH ORGANIZATIONS 175
TABLE 54 INDICATIVE LIST OF COLLABORATIONS WITH CROS 175
TABLE 55 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 176
12.4 RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES 177
12.4.1 SEGMENT TO REGISTER HIGHEST CAGR OVER FORECAST PERIOD 177
TABLE 56 INDICATIVE LIST OF RESEARCH COLLABORATIONS 177
TABLE 57 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 178
13 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY REGION 179
13.1 INTRODUCTION 180
TABLE 58 ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY REGION, 2021–2028 (USD MILLION) 180
13.2 NORTH AMERICA 180
13.2.1 NORTH AMERICA: RECESSION IMPACT 180
FIGURE 44 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET SNAPSHOT 181
TABLE 59 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 182
TABLE 60 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021–2028 (USD MILLION) 182
TABLE 61 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 182
TABLE 62 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 183
TABLE 63 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 183
TABLE 64 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021–2028 (USD MILLION) 184
TABLE 65 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021–2028 (USD MILLION) 184
TABLE 66 NORTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021–2028 (USD MILLION) 185
13.2.2 US 185
13.2.2.1 Strong economy and trend of early adoption of technologies to drive market 185
FIGURE 45 DISTRIBUTION OF R&D COMPANIES, BY COUNTRY/REGION (2021 VS. 2022) 186
TABLE 67 US: INDICATIVE LIST OF STRATEGIC DEVELOPMENTS 186
TABLE 68 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021–2028 (USD MILLION) 187
TABLE 69 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 187
TABLE 70 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 188
TABLE 71 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA 2021–2028 (USD MILLION) 188
TABLE 72 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS 2021–2028 (USD MILLION) 189
TABLE 73 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021–2028 (USD MILLION) 189
TABLE 74 US: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021–2028 (USD MILLION) 190
13.2.3 CANADA 190
13.2.3.1 Growing research on AI technologies and emergence of new AI-based start-ups to support market growth 190
TABLE 75 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021–2028 (USD MILLION) 191
TABLE 76 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 191
TABLE 77 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 192
TABLE 78 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 192
TABLE 79 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021–2028 (USD MILLION) 193
TABLE 80 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021–2028 (USD MILLION) 193
TABLE 81 CANADA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021–2028 (USD MILLION) 194
13.2.4 MEXICO 194
13.2.4.1 Government initiatives to support market growth 194
TABLE 82 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021–2028 (USD MILLION) 194
TABLE 83 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 195
TABLE 84 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 195
TABLE 85 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 196
TABLE 86 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021–2028 (USD MILLION) 196
TABLE 87 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021–2028 (USD MILLION) 197
TABLE 88 MEXICO: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021–2028 (USD MILLION) 197
13.3 EUROPE 197
13.3.1 EUROPE: RECESSION IMPACT 198
TABLE 89 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 199
TABLE 90 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021–2028 (USD MILLION) 199
TABLE 91 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 200
TABLE 92 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 200
TABLE 93 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 201
TABLE 94 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021–2028 (USD MILLION) 201
TABLE 95 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021–2028 (USD MILLION) 202
TABLE 96 EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021–2028 (USD MILLION) 202
13.3.2 UK 202
13.3.2.1 UK to hold largest share in Europe 202
TABLE 97 UK: INDICATIVE LIST OF STRATEGIC DEVELOPMENTS 203
TABLE 98 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021–2028 (USD MILLION) 204
TABLE 99 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 204
TABLE 100 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 205
TABLE 101 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 205
TABLE 102 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021–2028 (USD MILLION) 206
TABLE 103 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021–2028 (USD MILLION) 206
TABLE 104 UK: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021–2028 (USD MILLION) 207
13.3.3 GERMANY 207
13.3.3.1 Government support and favorable training programs to propel market growth 207
TABLE 105 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021–2028 (USD MILLION) 208
TABLE 106 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 208
TABLE 107 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 209
TABLE 108 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 209
TABLE 109 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021–2028 (USD MILLION) 210
TABLE 110 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021–2028 (USD MILLION) 210
TABLE 111 GERMANY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021–2028 (USD MILLION) 211
13.3.4 FRANCE 211
13.3.4.1 Strong government support and favorable strategies & initiatives to drive market 211
TABLE 112 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021–2028 (USD MILLION) 211
TABLE 113 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 212
TABLE 114 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 212
TABLE 115 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 213
TABLE 116 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021–2028 (USD MILLION) 213
TABLE 117 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021–2028 (USD MILLION) 214
TABLE 118 FRANCE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021–2028 (USD MILLION) 214
13.3.5 ITALY 214
13.3.5.1 Strong pharmaceutical industry to support market growth 214
TABLE 119 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021–2028 (USD MILLION) 215
TABLE 120 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 215
TABLE 121 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 216
TABLE 122 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 216
TABLE 123 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021–2028 (USD MILLION) 217
TABLE 124 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021–2028 (USD MILLION) 217
TABLE 125 ITALY: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021–2028 (USD MILLION) 218
13.3.6 REST OF EUROPE 218
TABLE 126 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021–2028 (USD MILLION) 218
TABLE 127 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 219
TABLE 128 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 219
TABLE 129 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 220
TABLE 130 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021–2028 (USD MILLION) 220
TABLE 131 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021–2028 (USD MILLION) 221
TABLE 132 REST OF EUROPE: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021–2028 (USD MILLION) 221

13.4 ASIA PACIFIC 222
13.4.1 ASIA PACIFIC: RECESSION IMPACT 222
TABLE 133 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 223
TABLE 134 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021–2028 (USD MILLION) 223
TABLE 135 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 223
TABLE 136 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 224
TABLE 137 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 224
TABLE 138 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021–2028 (USD MILLION) 225
TABLE 139 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021–2028 (USD MILLION) 225
TABLE 140 ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021–2028 (USD MILLION) 226
13.4.2 JAPAN 226
13.4.2.1 Japan to dominate APAC market 226
TABLE 141 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021–2028 (USD MILLION) 227
TABLE 142 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 227
TABLE 143 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 228
TABLE 144 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 228
TABLE 145 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021–2028 (USD MILLION) 229
TABLE 146 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021–2028 (USD MILLION) 229
TABLE 147 JAPAN: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021–2028 (USD MILLION) 230
13.4.3 CHINA 230
13.4.3.1 Growing CMO market and cross-industry collaborations to drive market 230
TABLE 148 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021–2028 (USD MILLION) 231
TABLE 149 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 231
TABLE 150 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 232
TABLE 151 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 232
TABLE 152 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021–2028 (USD MILLION) 233
TABLE 153 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021–2028 (USD MILLION) 233
TABLE 154 CHINA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021–2028 (USD MILLION) 234
13.4.4 INDIA 234
13.4.4.1 Steady adoption of AI technologies to support market growth 234
TABLE 155 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021–2028 (USD MILLION) 235
TABLE 156 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 235
TABLE 157 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 236
TABLE 158 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 236
TABLE 159 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021–2028 (USD MILLION) 237
TABLE 160 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021–2028 (USD MILLION) 237
TABLE 161 INDIA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021–2028 (USD MILLION) 238
13.4.5 REST OF ASIA PACIFIC 238
TABLE 162 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021–2028 (USD MILLION) 239
TABLE 163 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 239
TABLE 164 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 240
TABLE 165 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 240
TABLE 166 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021–2028 (USD MILLION) 241
TABLE 167 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021–2028 (USD MILLION) 241
TABLE 168 REST OF ASIA PACIFIC: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021–2028 (USD MILLION) 242
13.5 SOUTH AMERICA 242
13.5.1 SHORTAGE OF SKILLED LABOR AND GROWING REQUIREMENTS TO DRIVE AI ADOPTION 242
13.5.2 SOUTH AMERICA: RECESSION IMPACT 243
TABLE 169 SOUTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021–2028 (USD MILLION) 243
TABLE 170 SOUTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 243
TABLE 171 SOUTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 244
TABLE 172 SOUTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 244
TABLE 173 SOUTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021–2028 (USD MILLION) 245
TABLE 174 SOUTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021–2028 (USD MILLION) 245
TABLE 175 SOUTH AMERICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021–2028 (USD MILLION) 246

13.6 MIDDLE EAST & AFRICA 246
13.6.1 LIMITED COMPANY PRESENCE AND LARGE SCOPE FOR GROWTH TO FAVOR AI MARKET 246
13.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT 246
TABLE 176 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY OFFERING, 2021–2028 (USD MILLION) 247
TABLE 177 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 247
TABLE 178 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET FOR MACHINE LEARNING, BY TYPE, 2021–2028 (USD MILLION) 248
TABLE 179 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION) 248
TABLE 180 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY PROCESS, 2021–2028 (USD MILLION) 249
TABLE 181 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY USE CASE, 2021–2028 (USD MILLION) 249
TABLE 182 MIDDLE EAST & AFRICA: ARTIFICIAL INTELLIGENCE IN DRUG DISCOVERY MARKET, BY END USER, 2021–2028 (USD MILLION) 250
14 COMPETITIVE LANDSCAPE 251
14.1 KEY PLAYER STRATEGIES/RIGHT TO WIN 251
TABLE 183 OVERVIEW OF STRATEGIES ADOPTED BY KEY AI IN DRUG DISCOVERY PLAYERS, FEBRUARY 2021– MAY 2022 252
14.2 REVENUE ANALYSIS 256
FIGURE 46 REVENUE ANALYSIS OF TOP MARKET PLAYERS, 2022 256
14.3 MARKET SHARE ANALYSIS 257
FIGURE 47 AI IN DRUG DISCOVERY MARKET: MARKET SHARE ANALYSIS, 2022 258
TABLE 184 AI IN DRUG DISCOVERY MARKET: DEGREE OF COMPETITION 258
14.4 COMPANY EVALUATION MATRIX 260
14.4.1 STARS 260
14.4.2 EMERGING LEADERS 260
14.4.3 PERVASIVE PLAYERS 260
14.4.4 PARTICIPANTS 261
FIGURE 48 AI IN DRUG DISCOVERY MARKET: COMPANY EVALUATION MATRIX, 2022 261
14.4.5 COMPANY FOOTPRINT 262
TABLE 185 USE CASE FOOTPRINT (24 COMPANIES) 262
TABLE 186 PROCESS FOOTPRINT (24 COMPANIES) 263
TABLE 187 REGION FOOTPRINT (24 COMPANIES) 264
TABLE 188 COMPANY FOOTPRINT (24 COMPANIES) 265
14.5 START-UP/SME EVALUATION MATRIX 266
14.5.1 PROGRESSIVE COMPANIES 266
14.5.2 RESPONSIVE COMPANIES 266
14.5.3 DYNAMIC COMPANIES 266
14.5.4 STARTING BLOCKS 266
FIGURE 49 AI IN DRUG DISCOVERY MARKET: START-UP/SME EVALUATION MATRIX, 2022 267
14.5.5 AI IN DRUG DISCOVERY MARKET: COMPETITIVE BENCHMARKING 268
TABLE 189 AI IN DRUG DISCOVERY MARKET: DETAILED LIST OF KEY SMES/START-UPS 268
TABLE 190 USE CASE FOOTPRINT (START-UPS/SMES) 269
TABLE 191 PROCESS FOOTPRINT (START-UPS/SMES) 270
TABLE 192 REGION FOOTPRINT (START-UPS/SMES) 270
TABLE 193 COMPANY FOOTPRINT (START-UPS/SMES) 271
14.6 COMPETITIVE SCENARIOS AND TRENDS 271
14.6.1 PRODUCT LAUNCHES & ENHANCEMENTS 271
TABLE 194 AI IN DRUG DISCOVERY MARKET: PRODUCT LAUNCHES & ENHANCEMENTS, 2021–2023 271
14.6.2 DEALS 273
TABLE 195 AI IN DRUG DISCOVERY MARKET: DEALS, 2021–2023 273
14.6.3 OTHER DEVELOPMENTS 274
TABLE 196 AI IN DRUG DISCOVERY MARKET: OTHER DEVELOPMENTS, 2021–2023 274
15 COMPANY PROFILES 276
15.1 KEY PLAYERS 276
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
15.1.1 NVIDIA CORPORATION 276
TABLE 197 NVIDIA CORPORATION: COMPANY OVERVIEW 276
FIGURE 50 NVIDIA CORPORATION: COMPANY SNAPSHOT, 2022 277
TABLE 198 NVIDIA CORPORATION: PRODUCTS/SOLUTIONS/SERVICES OFFERED 278
TABLE 199 NVIDIA CORPORATION: PRODUCT/SERVICE LAUNCHES 279
TABLE 200 NVIDIA CORPORATION: DEALS 280
15.1.2 EXSCIENTIA 284
TABLE 201 EXSCIENTIA: COMPANY OVERVIEW 284
FIGURE 51 EXSCIENTIA: COMPANY SNAPSHOT (2022) 285
TABLE 202 EXSCIENTIA: PRODUCTS/SOLUTIONS/SERVICES OFFERED 285
TABLE 203 EXSCIENTIA: PRODUCT/SERVICE LAUNCHES 287
TABLE 204 EXSCIENTIA: DEALS 287
TABLE 205 EXSCIENTIA: OTHER DEVELOPMENTS 292
15.1.3 GOOGLE 294
TABLE 206 GOOGLE: COMPANY OVERVIEW 294
FIGURE 52 GOOGLE: COMPANY SNAPSHOT (2022) 295
TABLE 207 GOOGLE: PRODUCTS/SOLUTIONS/SERVICES OFFERED 296
TABLE 208 GOOGLE: PRODUCT/SERVICE LAUNCHES 297
TABLE 209 GOOGLE: DEALS 297
TABLE 210 GOOGLE: OTHER DEVELOPMENTS 298
15.1.4 BENEVOLENTAI 299
TABLE 211 BENEVOLENTAI: COMPANY OVERVIEW 299
FIGURE 53 BENEVOLENTAI: COMPANY SNAPSHOT (2022) 299
TABLE 212 BENEVOLENTAI: PRODUCTS/SOLUTIONS/SERVICES OFFERED 300
TABLE 213 BENEVOLENTAI: DEALS 300
15.1.5 RECURSION 303
TABLE 214 RECURSION: COMPANY OVERVIEW 303
FIGURE 54 RECURSION: COMPANY SNAPSHOT (2022) 303
TABLE 215 RECURSION: PRODUCTS/SOLUTIONS/SERVICES OFFERED 304
TABLE 216 RECURSION: PRODUCT/SERVICE LAUNCHES 304
TABLE 217 RECURSION: DEALS 305
TABLE 218 RECURSION: OTHER DEVELOPMENTS 306
15.1.6 INSILICO MEDICINE 307
TABLE 219 INSILICO MEDICINE: COMPANY OVERVIEW 307
TABLE 220 INSILICO MEDICINE: PRODUCTS/SOLUTIONS/SERVICES OFFERED 308
TABLE 221 INSILICO MEDICINE: PRODUCT/SERVICE LAUNCHES 309
TABLE 222 INSILICO MEDICINE: DEALS 310
TABLE 223 INSILICO MEDICINE: OTHER DEVELOPMENTS 313
15.1.7 SCHRÖDINGER, INC. 314
TABLE 224 SCHRÖDINGER, INC.: COMPANY OVERVIEW 314
FIGURE 55 SCHRÖDINGER, INC.: COMPANY SNAPSHOT (2022) 315
TABLE 225 SCHRÖDINGER, INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED 315
TABLE 226 SCHRÖDINGER, INC.: DEALS 316
TABLE 227 SCHRÖDINGER, INC.: OTHER DEVELOPMENTS 318
15.1.8 MICROSOFT CORPORATION 319
TABLE 228 MICROSOFT CORPORATION: COMPANY OVERVIEW 319
FIGURE 56 MICROSOFT CORPORATION: COMPANY SNAPSHOT (2023) 320
TABLE 229 MICROSOFT CORPORATION: PRODUCTS/SOLUTIONS/SERVICES OFFERED 321
TABLE 230 MICROSOFT CORPORATION: SERVICE LAUNCHES 321
TABLE 231 MICROSOFT CORPORATION: DEALS 322
15.1.9 ATOMWISE INC. 323
TABLE 232 ATOMWISE INC.: COMPANY OVERVIEW 323
TABLE 233 ATOMWISE INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED 323
TABLE 234 ATOMWISE INC.: DEALS 324
15.1.10 ILLUMINA, INC. 325
TABLE 235 ILLUMINA, INC.: COMPANY OVERVIEW 325
FIGURE 57 ILLUMINA, INC.: COMPANY SNAPSHOT (2022) 326
TABLE 236 ILLUMINA, INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED 326
TABLE 237 ILLUMINA, INC.: PRODUCT/SERVICE LAUNCHES 327
TABLE 238 ILLUMINA, INC.: DEALS 328
15.1.11 NUMEDII, INC. 330
TABLE 239 NUMEDII, INC.: COMPANY OVERVIEW 330
TABLE 240 NUMEDII, INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED 331
15.1.12 XTALPI INC. 332
TABLE 241 XTALPI INC.: COMPANY OVERVIEW 332
TABLE 242 XTALPI INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED 332
TABLE 243 XTALPI INC.: DEALS 333
15.1.13 IKTOS 335
TABLE 244 IKTOS: COMPANY OVERVIEW 335
TABLE 245 IKTOS: PRODUCTS/SOLUTIONS/SERVICES OFFERED 336
TABLE 246 IKTOS: DEALS 337
TABLE 247 IKTOS: OTHER DEVELOPMENTS 340
15.1.14 TEMPUS LABS 341
TABLE 248 TEMPUS LABS: COMPANY OVERVIEW 341
TABLE 249 TEMPUS LABS: PRODUCTS/SOLUTIONS/SERVICES OFFERED 341
TABLE 250 TEMPUS LABS: PRODUCT/SERVICE LAUNCHES 342
TABLE 251 TEMPUS LABS: DEALS 342
TABLE 252 TEMPUS LABS: OTHER DEVELOPMENTS 344
15.1.15 DEEP GENOMICS, INC. 345
TABLE 253 DEEP GENOMICS, INC.: COMPANY OVERVIEW 345
TABLE 254 DEEP GENOMICS, INC.: PRODUCTS/SERVICES OFFERED 345
TABLE 255 DEEP GENOMICS, INC.: DEALS 346
TABLE 256 DEEP GENOMICS, INC.: OTHER DEVELOPMENTS 346
15.1.16 VERGE GENOMICS 347
TABLE 257 VERGE GENOMICS: COMPANY OVERVIEW 347
TABLE 258 VERGE GENOMICS: PRODUCTS/SERVICES OFFERED 347
TABLE 259 VERGE GENOMICS: DEALS 348
15.1.17 BENCHSCI 349
TABLE 260 BENCHSCI: COMPANY OVERVIEW 349
TABLE 261 BENCHSCI: PRODUCTS/SOLUTIONS/SERVICES OFFERED 349
TABLE 262 BENCHSCI: PRODUCT/SERVICE LAUNCHES 350
TABLE 263 BENCHSCI: OTHER DEVELOPMENTS 350
15.1.18 INSITRO 351
TABLE 264 INSITRO: COMPANY OVERVIEW 351
TABLE 265 INSITRO: PRODUCTS/SOLUTIONS/SERVICES OFFERED 351
TABLE 266 INSITRO: OTHER DEVELOPMENTS 352
15.1.19 VALO HEALTH 353
TABLE 267 VALO HEALTH: COMPANY OVERVIEW 353
TABLE 268 VALO HEALTH: PRODUCTS/SOLUTIONS/SERVICES OFFERED 353
TABLE 269 VALO HEALTH: DEALS 354
TABLE 270 VALO HEALTH: OTHER DEVELOPMENTS 355
15.1.20 BPGBIO, INC. 356
TABLE 271 BPGBIO, INC.: COMPANY OVERVIEW 356
TABLE 272 BPGBIO, INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED 356
TABLE 273 BPGBIO, INC.: DEALS 357
15.2 OTHER EMERGING PLAYERS 358
15.2.1 PREDICTIVE ONCOLOGY, INC. 358
15.2.2 LABCORP 359
15.2.3 IQVIA INC. 360
15.2.4 TENCENT HOLDINGS LIMITED 361
15.2.5 CELSIUS THERAPEUTICS 362
15.2.6 CYTOREASON 363
15.2.7 OWKIN, INC. 364
15.2.8 CLOUD PHARMACEUTICALS 364
15.2.9 EVAXION BIOTECH 365
15.2.10 STANDIGM 365
15.2.11 BIOAGE LABS 366
15.2.12 ENVISAGENICS 366
15.2.13 ARIA PHARMACEUTICALS, INC. 367
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
16 APPENDIX 368
16.1 DISCUSSION GUIDE 368
16.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 375
16.3 CUSTOMIZATION OPTIONS 377
16.4 RELATED REPORTS 378
16.5 AUTHOR DETAILS 379

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の創薬における人工知能（AI）市場（～2028年）：提供別、工程別（ターゲット選択、バリデーション、リード生成、最適化）、ドラッグデザイン別（低分子、ワクチン、抗体、PK/PD）、ドライラボ別、ウェットラボ別（シングルセル解析）、地域別(Artificial Intelligence / AI in Drug Discovery Market by Offering, Process (Target selection, Validation, Lead generation, optimization), Drug Design (Small molecule, Vaccine, Antibody, PK/PD), Dry Lab, Wet Lab (Single Cell analysis) & Region - Global Forecast to 2028)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp